Personalized acyclovir dosing in overweight and obese volunteers
Treatments studied
Part of Hormones & metabolism clinical trials.
This Phase 1 study tests how to adjust acyclovir dosing based on body weight and kidney function. It includes healthy volunteers across normal weight, overweight, and obesity levels to better understand how the drug moves through the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 39.9 BMI (normal weight, overweight, or obesity), in the specific study weight groups
- Have kidney function measured as eGFR above 50 ml/min
- Have good usable veins for taking blood samples over time
- Be able to participate safely as a woman (use birth control if able, or be postmenopausal) and agree in writing
- Not take medicines that interfere with acyclovir (or that can harm kidneys), such as diuretics, certain anti-inflammatory pain meds (NSAIDs), statins, cimetidine, probenecid, mycophenolate, lithium, or anti-rejection medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called ACCG-2671 to see how safe it is and how your body handles it. It's an early-stage trial, so the main focus is on safety and tolerability. The study has different parts: one for people with normal weight and one for people with higher weight who are already taking a GLP-1 injection for weight loss.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This study tests an injected medication called ABBV-295 for adults with obesity. The goal is to see how safe it is and how the body processes it. You may join if you have a BMI between 30 and 45 and are generally healthy, and you haven't been on other weight loss treatments recently.
This trial tests a new medicine called AZD1043 in healthy adults who are overweight or have obesity. It aims to see if the medicine is safe and how the body handles it.
This early-stage study tests a new investigational medication in three groups: healthy adults with normal weight, adults who are overweight or obese, and men with type 1 diabetes who are also overweight. The research aims to understand how safe the medication is and how the body processes it.
This Phase 1 trial tests a new medicine called ALN-6222 in people with obesity to see if it's safe and how well it works. The study focuses on adults with a BMI between 30 and 40 who don't have diabetes.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.